Observational Epidemiological Study of disease progression and therapeutic approach in prostate Cancer Patients
Not Applicable
Completed
- Conditions
- Prostate cancerCancer
- Registration Number
- ISRCTN19893319
- Lead Sponsor
- Astelas Pharma S.A. (Spain)
- Brief Summary
2016 results in https://pubmed.ncbi.nlm.nih.gov/26723895/ (added 25/06/2020) 2017 results in https://pubmed.ncbi.nlm.nih.gov/28285790/ (added 25/06/2020) 2019 results in https://pubmed.ncbi.nlm.nih.gov/29891440/ (added 25/06/2020)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 4087
Inclusion Criteria
Patient that was included in the study with code CaP01-10 with newly diagnosed, histopathologically confirmed PCa in any stage, between 1 January and 31 December 2010
Exclusion Criteria
Patients who have withdrawn their informed consent to take part in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Biochemical progression-free survival at 1, 2 and 3 years after being diagnosed in 2010<br> 2. Clinical progression-free survival at 1, 2 and 3 years after being diagnosed in 2010<br>
- Secondary Outcome Measures
Name Time Method <br> 1. Patient?s clinical variables at the time of diagnosis associated with the 1 and 3 year survival<br> 2. Therapeutic approach<br> 3. Cancer-specific survival and overall survival<br>